Latest Updates
-
Alia Bhatt's Ethnic Outfits Stole Every Spotlight At Best Friend Akansha Ranjan Kapoor's Wedding Celebrations -
Jagannath Rath Yatra 2026: 10 Iconic Odia Delicacies Every Visitor Must Try In Puri -
Katrina Kaif Shares Birthday Dump, Gives Glimpse Of Baby Vihaan: 10 Little Details Worth A Closer Look -
Sita Vs Shurpanakha! Sai Pallavi And Rakul Preet Singh's Sarees Ruled The Ramayana Pratham Sankalp Event -
National Film Awards 2026: From Yami Gautam's Big Win To Dhanush's Double Triumph—7 Biggest Takeaways -
Things To Do In The Rain: 10 Cozy Monsoon Ideas That Will Make You Love Rainy Days Even More -
Sarcoma Awareness Month 2026: Can A Sports Injury Hide Sarcoma? Medical Oncologist Explains The Warning Signs -
Who Is Gitanjali J. Angmo? Why Sonam Wangchuk's Wife's Statement On His Treatment Is Making Headlines -
Jennifer Winget's Viral Bridal Gown Trial Video Reveals The Intricate Details Behind Her Bespoke Couture Look -
Happy Birthday Bhumi Pednekar: How Rishikesh, Pushkar And Meditation Helped The Actress Find Inner Peace
Zydus Lifesciences Launches Oral Drug Bemdac For Treating Bad Cholesterol
Zydus Lifesciences on Friday said it has launched in India its Bempedoic acid drug under the Bemdac brand for treatment of uncontrolled levels of bad cholesterol.

Bemdac (Bempedoic acid) is a new class of drug which is orally administered and offers a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite lifestyle modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management, the company said in a regulatory filing.
"With Bemdac we are happy to introduce a first-in-India therapy to address the unmet medical need of people suffering from uncontrolled LDL-c," Zydus Lifesciences Managing Director Sharvil Patel said.
Stating that Bemdac is an important addition to Zydus' portfolio of medicines for managing dyslipidemia and cholesterol, Patel said the mission is to empower patients with a better quality of life through effective disease management and with Bemdac the company has taken a great leap ahead in this endeavour.

The company said LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like a heart attack or stroke.
Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases. Citing various studies, Zydus said, 8 out of 10 Indians are dyslipidemic1 and 112 million adults suffer from high levels of LDL-c; 7 out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c.
Besides this, 5.4 million Indians are found to be intolerant to statin therapy, it added. Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins. This is a huge unmet healthcare need that Bemdac addresses, Zydus claimed.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications